SEC Form 4 · accession 0001193125-26-361184
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Teresa Brophy Bair
Officer — Chief Legal Officer
Period of report
Aug 19, 2026
Accepted (ET)
Aug 21, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001422143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 19, 2026 | S | 31,487 | $12.63 | D | 195,444 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares sold were acquired by the Reporting Person upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2026.
- F2This transaction was executed in multiple trades at prices ranging from $12.44 to $12.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.